JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030

Key Takeaways JNJ's oncology sales rose 20.6% to $18.52B on strong growth of key cancer drugs.JNJ targets $50B in oncology sales by decade-end.A $3.05B deal for Halda Therapeutics adds targeted cancer medicines to JNJ's portfolio.Johnson & Johnson (JNJ) is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors.Its Oncology segment, at present, comprises around 27% of its total revenues. Its oncology sales rose 20.6% on an operational basis ...